Rate Benchmarking
Compare your rates with similar providers.
Select a published rate, define comparable providers, and see where that rate falls in your market.
See a sample rate comparisonHCPCS J0702 (Betamethasone Sod Phos Acetate) Fee Schedule
Last Verified: September 2026
Healthcare providers use this code to document and receive reimbursement for visits that address moderate-level medical decision-making, often including multiple diagnoses or prescription management.
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg
| Key Fact | Detail |
|---|---|
| Service Type | Drugs Administered Other than Oral Method Drugs, Administered by Injection |
| Common Place of Service | 11 - Office None 20 - Urgent Care Facility |
| Complexity Level | Low |
| Medicaid Fee Schedule | View Medicaid rates for J0702 |
| Medicare Payment Limit | $6.956  |
| WAC Price | Lorem ipsum dolor sit amet consectetur Lorem ipsum dolor sit amet consectetur VisitBuyandBill.com |
| Related NDC Codes | • 78206-0118-01 - CELESTONE SOLUSPAN (MDV) 3 MG/1 ML-3 MG/1 ML |
National average reimbursement for HCPCS J0702 by major payers:
$7.13
$7.67
$8.72
$7.86
Compare published rates across providers.
Choose a payer to see a sample of rates for HCPCS J0702.
HCPCS J0702
5 of 25 sample ratesHigher to lower in this preview
Chu Chen
Merrimack Valley Pediatric Associates, Inc.
$15.00Published rateParvez Asmat
Slocum Dickson Medical Group PLLC
$7.51Published rateAndrea Moehringer
Slocum Dickson Medical Group PLLC
$7.51Published rateDaniel Ernst
Slocum Dickson Medical Group PLLC
$6.40Published rateElizabeth Westen
Slocum Dickson Medical Group PLLC
$6.40Published rate
Get a free rate benchmark for your specialty.
Choose your state and specialty to build a report from payer-published rates.
Use market rates to prepare your payer proposal.
Payer Contract Negotiation
Draft a fee schedule renegotiation letter.
Use your fee schedule and market benchmarks to set target rates and draft a letter for your payer.
See a sample payer proposalHCPCS J0702 vs. Other Drugs, Administered by Injection Codes
The HCPCS J0702 code is part of the Drugs Administered Other than Oral Method services used for Drugs, Administered by Injection. It represents a moderate-complexity encounter and is one of several codes that vary based on time spent, level of medical decision-making, and documentation requirements.
The HCPCS J0702 code involves more provider time and moderate medical decision-making, unlike lower-level codes that require less time and simpler assessments. It typically includes multiple diagnoses, medication management, or test interpretation, leading to higher reimbursement and more detailed documentation requirements.
| Code | Complexity | Description |
|---|---|---|
| 78206-0118-01-NDC | Moderate | CELESTONE SOLUSPAN (MDV) 3 MG/1 ML-3 MG/1 ML |
| J0701-HCPCS | Low | Injection, cefepime hydrochloride (baxter), not therapeutically equivalent to maxipime, 500 mg |
| J0702-HCPCS | Low | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
| J0703-HCPCS | Low | Injection, cefepime hydrochloride (b braun), not therapeutically equivalent to maxipime, 500 mg |
What is a fee schedule?
A fee schedule is a list of fixed prices that healthcare providers charge for specific services, including HCPCS J0702. These prices vary depending on payer type (Medicare, Medicaid, private insurance), geographic location, and provider contracts.
Understanding the J0702 fee schedule helps patients estimate costs and providers optimize billing for accurate reimbursements.
Factors that affect fee schedules
Medicare & Medicaid Rates
Government-set reimbursement amounts
Private Insurance Rates
Negotiated rates between providers and insurance companies
Geographic Location
Costs may be higher in urban areas.
Provider Type
Hospital providers may have different rates than private practice.
FREE SAMPLE MARKET COMPARISON
Let's review your payer contracts side-by-side with the market.
Bring your top codes (like HCPCS J0702) and we'll show you how you compare in 15 minutes or less.